BIIB Jan 2025 300.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:38AM EDT. Market open.
| Previous close | 1.9100 |
| Open | 1.8000 |
| Bid | 2.0500 |
| Ask | 2.5000 |
| Strike | 300.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.8000 - 2.0700 |
| Contract range | N/A |
| Volume | |
| Open interest | 376 |
ZacksSage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
ZacksThe Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
GuruFocus.comDecoding Biogen Inc (BIIB): A Strategic SWOT Insight
Insightful Analysis of Biogen Inc's Financials and Strategic Positioning
© 2024 Yahoo. All rights reserved.